Upward movement4 Oct 2021 17:02
Commercialisation of cancer vulnerability test due to start Q4 2021..........completed move to far larger premises at end of Sept 21......share price driven down..........Directors and ex-Directors hold 33%.........other significant shareholders total 35%...........only 94m shares in issue.....these will be hard to get hold of once the upward move starts.
As new CEO, Jon Burrows, stated in their recent RNS: Dr Jon Burrows, CEO of Oxford BioDynamics, said: "With OBD's strong growth outlook, our move to this larger, purpose-built facility is key to the execution of our strategy. It is important in particular as we prepare for commercialization of EpiSwitch® CiRT - our Checkpoint Inhibitor Response Test for cancer - in Q4, and with respect to our recent FNIH PACT award [3]. These are linked to the immune-oncology interests of the pharma industry, which has generated significant attention, and we expect more activity from these groups.